Cancer Research Versailles No Abst Advances in Breast Cancer Research
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Cancer Research 66, 10885, November 15, 2006. doi: 10.1158/0008-5472.CAN-06-1311
© 2006 American Association for Cancer Research
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Selleri, C.
Right arrow Articles by Ragno, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Selleri, C.
Right arrow Articles by Ragno, P.

Cell, Tumor, and Stem Cell Biology

In vivo Activity of the Cleaved Form of Soluble Urokinase Receptor: A New Hematopoietic Stem/Progenitor Cell Mobilizer

Carmine Selleri1, Nunzia Montuori2, Patrizia Ricci1, Valeria Visconte3, Antonio Baiano4, Maria Vincenza Carriero5, Bruno Rotoli1, Guido Rossi3 and Pia Ragno2

1 Department of Biochemistry and Medical Biotechnology, 2 Institute of Experimental Endocrinology and Oncology (National Research Council), 3 Department of Cellular and Molecular Biology and Pathology, and 4 Veterinary Service Center, "Federico II" University; and 5 Department of Experimental Oncology, National Cancer Institute, Naples, Italy

Requests for reprints: Pia Ragno, Istituto di Endocrinologia ed Oncologia Sperimentale, Consiglio Nazionale delle Ricerche, Via Pansini 5, I-80131, Naples, Italy. Phone: 39-081-746-3309; Fax: 39-081-770-1016; E-mail: ragno{at}unina.it.


   Abstract
Top
 Abstract
Introduction
 Materials and Methods
 Results
 Discussion
 References
 
Cleaved forms of soluble urokinase receptor (c-suPAR) have been detected in body fluids from patients affected by various tumors. We recently reported increased c-suPAR levels in sera of healthy donors during granulocyte colony-stimulating factor (G-CSF)–induced mobilization of CD34+ hematopoietic stem cells (HSC). In vitro, c-suPAR or its derived chemotactic peptide (uPAR84-95) stimulated migration of human CD34+ HSCs and inactivated CXCR4, the chemokine receptor primarily responsible for HSC retention in bone marrow. These results suggested that c-suPAR could potentially contribute to regulate HSC trafficking from and to bone marrow. Therefore, we investigated uPAR84-95 effects on mobilization of mouse CD34+ hematopoietic stem/progenitor cells (HSC/HPC). We first showed that uPAR84-95 stimulated in vitro dose-dependent migration of mouse CD34+ M1 leukemia cells and inactivated murine CXCR4. uPAR84-95 capability to induce mouse HSC/HPC release from bone marrow and migration into the circulation was then investigated in vivo. uPAR84-95 i.p. administration induced rapid leukocytosis, which was associated with an increase in peripheral blood CD34+ HSCs/HPCs. In vitro colony assays confirmed that uPAR84-95 mobilized hematopoietic progenitors, showing an absolute increase in circulating colony-forming cells. uPAR84-95 mobilizing activity was comparable to that of G-CSF; however, neither synergistic nor additive effect was observed in combining the two molecules. These findings show for the first time in vivo biological effects of c-suPAR. Its capability to mobilize HSCs suggests potential clinical applications in HSC transplantation. (Cancer Res 2006; 66(22): 10885-90)


   Introduction
Top
 Abstract
 Introduction
Materials and Methods
 Results
 Discussion
 References
 
The urokinase-type plasminogen activator (uPA) is a serine protease that activates plasminogen to plasmin and binds to a specific high-affinity cell-surface receptor, uPAR (CD87). uPAR is formed by three homologous domains of ~90 amino acids (D1, D2, and D3, as numbered from the NH2 terminus) and is anchored to the cell membrane through a glycosyl-phosphatidylinositol (GPI) tail, attached to the COOH-terminal D3 domain (1). uPAR capability to transduce cell signals is likely due to its association with other cell-surface molecules, such as integrins and receptors for fMet-Leu-Phe (fMLP), a potent leukocyte chemoattractant (2). uPAR can be shed by the cell surface; soluble uPAR (suPAR) has been detected in plasma and urine from patients with various diseases (3). Both cell surface and soluble uPAR can be proteolytically cleaved in the D1-D2 linker region, thus generating truncated forms of GPI-uPAR (c-uPAR) and suPAR (c-suPAR), lacking D1. Cleaved uPAR forms can vary at the NH2 terminus, according to the protease that cleaves the receptor and that may or may not disrupt a specific sequence, corresponding to amino acids 88-92 (SRSRY), which is involved in cell migration. In fact, cleaved suPAR or a uPAR-derived peptide containing the SRSRY sequence (uPAR84-95) is able to activate fMLP receptors, thus inducing migration of monocytes, basophils, and hematopoietic stem cells (HSC; refs. 4–6). The human uPAR84-95 peptide is not species specific because it exerts its chemotactic activity also on murine uPAR–/– fibroblasts, 3T3, and LB6 cells and on rat aortic smooth muscle cells (7).

Cleaved forms of suPAR have been detected in biological fluids of individuals affected by breast and ovarian cancer, acute myeloid leukemia, and neurologic disorders (3); recently, a significant increase in SRSRY-containing c-suPAR has been observed in urine and serum from patients affected by colorectal and prostatic carcinomas as compared with healthy volunteers (8). However, a direct evidence of c-suPAR role in vivo has never been provided.

We have recently shown the involvement of c-suPAR in the mobilization of human CD34+ HSCs into peripheral blood (6). Mobilized peripheral blood HSCs have largely replaced bone marrow HSCs in transplantation procedures (9). Several agents are able to mobilize bone marrow HSCs; due to its potency and safety, the most common mobilizer is the granulocyte colony-stimulating factor (G-CSF; ref. 10). HSC mobilization involves ß1 and ß2 integrins, the stromal derived factor 1 (SDF1) chemokine, its receptor, CXCR4, and specific proteases; their relative role and importance have been only partially elucidated and are often controversial (11–14). Agents that down-regulate integrin activity or disrupt the SDF1-CXCR4 axis induce HSC release from bone marrow into the circulation. AMD3100, a pharmacologic antagonist of CXCR4, is an efficient HSC mobilizer both in humans and mice (15, 16).

We have recently reported that G-CSF administration to HSC healthy donors up-regulated uPAR expression in circulating myeloid precursors and monocytic cells and increased s-uPAR and c-suPAR levels in sera (6). c-suPAR and its derived peptide (uPAR84-95) induced in vitro migration of bone marrow HSCs by activating the high-affinity fMLP receptor (FPR). The uPAR peptide also abolished in vitro migration of HSCs towards SDF1.

These in vitro findings prompted us to examine the role of c-suPAR in HSC mobilization in vivo. To this end, we first investigated whether the uPAR84-95 chemotactic peptide was able to regulate in vitro migration of mouse M1 leukemia cells, which express the CD34 antigen and can be induced to differentiate by physiologic myelopoietic factors (17–19). The CD34 antigen is expressed also on murine hematopoietic stem and progenitor cells (HSC/HPC) capable of rapidly reconstituting and rescuing myeloablated mice (19–21). We then examined the in vivo effects of uPAR84-95 administration on mouse HSC/HPC mobilization.


   Materials and Methods
Top
 Abstract
 Introduction
 Materials and Methods
Results
 Discussion
 References
 
Reagents. Ninety-six-well microtiter plates were purchased from Costar (Cambridge, MA). Ficoll-Hypaque (specific gravity, 1,077), bovine serum albumin, and hydrocortisone sodium hemisuccinate were from Sigma Chemical Co. (St. Louis, MO). RPMI 1640 and heat-inactivated FCS were from Life Technologies (Gaithersburg, MD). Chemotaxis PVPF filters were purchased from Corning (Corning, NY) and the SDF1 from Peprotech (London, United Kingdom). Horseradish peroxidase–conjugated streptavidin, the biotinylation kit, and the enhanced chemiluminescence (ECL) detection kit were from Amersham International (Amersham, United Kingdom) and polyvinylidene fluoride (PVDF) filters were from Millipore (Windsor, MA). Red cell lysis buffer was from Becton Dickinson (Mountain View, CA). Phycoerythrin-conjugated antimouse CD34 monoclonal antibody was purchased from BD Biosciences PharMingen (Milan, Italy). Methylcellulose and the recombinant mouse growth factor cocktail were from Stem Cell Technologies (Vancouver, Canada). Recombinant human G-CSF (lenograstim) was purchased from Italfarmaco (Milan, Italy). The peptide uPAR84-95 (AVTYSRSRYLEC) and its scrambled version (TLVEYYSRASCR) were prepared by PRIMM (Milan, Italy).

Cell cultures. Mouse M1 leukemia cells (17) were grown in RPMI 1640 supplemented with 10% heat-inactivated FCS.

Cell migration assay. Cell migration assays were done in Boyden chambers with 5-µm pore size PVDF polycarbonate uncoated filters. Cells (2 x 105) were plated in the upper chamber in serum-free medium; 10–8 mol/L fMLP, various concentrations of uPAR-derived peptide (uPAR84-95), 100 ng/mL SDF1, or serum-free medium was added in the lower chamber. Cells were allowed to migrate for 90 minutes at 37°C, 5% CO2. Cells on the lower surface of the filter were then fixed in ethanol, stained with hematoxylin, and counted at 200x magnification (10 random fields per filter).

In a separate set of experiments, cells were preincubated for 30 minutes at 37°C with 10–4 mol/L fMLP, 10–7 mol/L uPAR84-95, or buffer.

Animals and experimental design. BALB/c mice (Charles River Laboratory, Lecco, Italy), 8 weeks of age, were fed with commercial rodent chow and acidified water for some days before use. All the experiments were approved by the animal care committee of our institution. Mice were injected i.p. with the peptide uPAR84-95 or its scrambled version (ScP) and with recombinant human G-CSF or buffer, in 200 µL PBS containing 0.1% albumin.

uPAR84-95 or ScP was injected daily for 2 days at the indicated doses; G-CSF (0.25 mg/kg) or buffer was administered daily for 5 days. Four hours after the last injection, mice were killed by CO2 asphyxiation and peripheral blood was obtained by cardiac puncture using a heparinized syringe. Each experimental group was composed of at least three mice.

Protein biotinylation. uPAR84-95 (2 mg/mL) was biotinylated with a biotinylation kit (Amersham) according to the instructions of the manufacturer. Biotinylated peptide was quantitated with Micro BCA Reagent (Pierce, Rockford, IL).

Detection of circulating biotinylated uPAR84-95 in vivo. To determine the levels of circulating biotinylated uPAR84-95 in vivo, serum was obtained from four mice at various intervals after a single i.p. injection of 20 µg biotinylated uPAR84-95. Triplicates of 1:10 mouse serum dilutions were analyzed by dot-blot onto a PVDF membrane. Biotinylated peptide was detected by hybridization with horseradish peroxidase–conjugated streptavidin and ECL. Dot-blots were analyzed by densitometric scanning and compared with dot-blots of various concentrations of biotinylated uPAR84-95.

Flow cytometry analysis. Whole blood containing ~1 x 106 nucleated cells was washed once with red cell lysis buffer and then with PBS. Cells were stained with 20 µL of a phycoerythrin-conjugated anti-mouse CD34 monoclonal antibody for 20 minutes at 4°C and then analyzed by FACScan flow cytometer (Becton Dickinson). At least 5 x 105 to 10 x 105 nucleated cells were acquired for each sample using the CellQuest software (Becton Dickinson) and the total number of CD34+ cells was calculated on the basis of their percentage. Equivalent gating on isotype-matched negative controls was used for background subtraction in all assays.

Colony-forming unit assay. The total number of WBC in the peripheral blood was determined. Peripheral blood mononuclear cells (PBMC) were isolated by density gradient centrifugation and plated in methylcellulose in the presence of a recombinant mouse growth factor cocktail, as previously described, to enumerate peripheral blood progenitor cells (16). Colony forming units (CFU) granulocyte-macrophage (CFU-GM), CFU granulocyte erythroid macrophage, megakaryocyte (CFU-GEMM), and blast-forming unit-erythroid (BFU-E) were counted after 8-day incubation at 5% CO2. Each experiment was done in triplicate.

Statistical analysis. Differences between groups were evaluated with the Student's t test. P ≤ 0.05 was considered statistically significant.


   Results
Top
 Abstract
 Introduction
 Materials and Methods
 Results
Discussion
 References
 
uPAR84-95 stimulates migration of mouse CD34+ M1 cells and inactivates murine CXCR4. We have recently reported that the uPAR-derived peptide uPAR84-95 stimulates migration of human CD34+ KG1 cells and CD34+ HSCs, by activating fMLP receptors, and inactivates CXCR4, the chemokine receptor primarily responsible for HSC retention in bone marrow (6, 22–25). We then investigated whether the same peptide is able to exert the same effects on mouse CD34+ M1 leukemia cells.

M1 cells were able to respond to the fMLP chemotactic stimulus, thus indicating that these cells express functional fMLP receptors (not shown). Therefore, fMLP receptors could potentially mediate uPAR84-95-induced migration of CD34+ M1 cells, as previously shown in human CD34+ HSCs. In fact, uPAR84-95 induced dose-dependent M1 cell migration (Fig. 1A ); homologous desensitization with fMLP confirmed the involvement of fMLP receptors, as previously reported for human CD34+ HSCs (not shown).


Figure 1
View larger version (14K):
[in this window]
[in a new window]
  		Figure 1. uPAR84-95 induces dose-dependent migration of mouse CD34+ M1 leukemia cells and inactivates murine CXCR4. A, mouse CD34+ M1 cells were plated in Boyden chambers and allowed to migrate toward uPAR84-95 at various concentrations. B, mouse CD34+ M1 cells, preincubated with buffer (–) or 10–7 mol/L uPAR84-95, were plated in Boyden chambers and allowed to migrate toward 100 ng/mL SDF1. One-hundred percent values represent cell migration in the absence of chemoattractants. Points and columns, mean of two experiments done in triplicate; bars, SD.

 
Moreover, we showed that CD34+ M1 cells were able to migrate toward SDF1; preincubation with uPAR84-95 almost abolished the SDF1-dependent chemotaxis, thus indicating that uPAR84-95 regulates CXCR4 activity also in mouse cells (Fig. 1B).

uPAR84-95 administration increases circulating WBCs and CD34+ HSCs/HPCs in mouse. In vitro migration experiments indicated that uPAR84-95 induces migration of hematopoietic cells and regulates CXCR4 activity in mouse, suggesting that this molecule might induce release of mouse HSCs/HPCs from bone marrow and promote their migration into the circulation in vivo. Therefore, we analyzed the effect of various doses of uPAR84-95 on mobilization of WBCs and HSCs/HPCs in mice.

Murine HSCs/HPCs express the CD34 antigen (19–21), which is largely expressed in all human HSCs; in mice, CD34 is present in HSCs that are capable of rapidly reconstituting and rescuing myeloablated mice (19–21). Thus, we analyzed CD34 expression on mobilized WBCs to identify circulating HSCs/HPCs.

uPAR84-95 or its scrambled peptide was administered daily for 2 days at concentrations of 0.3, 1.5, 3, and 6 mg/kg. The peptide concentration range was compatible with the doses of a CXCR4 agonist peptide (26) and of a CXCR2 agonist previously used to induce HSC mobilization in mice (22). uPAR84-95 caused rapid leukocytosis and induced a measurable increase in circulating CD34+ HSCs/HPCs, with a peak value at the 3 mg/kg dose (Fig. 2A and B , respectively). The increase in circulating CD34+ cells following uPAR84-95 administration was similar to that obtained by administration of other agents (9). These results indicate that the uPAR-derived chemotactic peptide is able to induce dose-dependent mobilization of WBCs and CD34+ cells in mouse, the optimal dose being 3 mg/kg.


Figure 2
View larger version (12K):
[in this window]
[in a new window]
  		Figure 2. uPAR84-95 administration increases circulating WBCs and CD34+ HSCs/HPCs in mice. BALB/c mice were injected i.p. daily for 2 days with the indicated doses of uPAR84-95 peptide ({diamondsuit}) or a scrambled version of this peptide ({blacksquare}). Four hours after the last injection, circulating WBCs were counted (A) and the CD34+ cell number was evaluated by flow cytometry (B). Points, mean of three experiments; bars, SEM.

 
To determine the levels of circulating uPAR84-95 after i.p. injection, mice were injected with biotinylated peptide; serum samples were collected at various intervals and analyzed by dot-blot. Dot-blots were analyzed by densitometric scanning and compared with dot-blots of biotinylated peptide at various concentrations. The peak of circulating biotinylated uPAR84-95 was observed at 1 to 2 hours after peptide injection (Fig. 3 ) and corresponded to 1.9 and 2.1 µg/mL, respectively. These results were compatible with the observed effects of the uPAR-derived peptide on WBC and CD34+ HSC/HPC mobilization. However, a single stimulation with uPAR84-95 induced only a very weak effect (not shown), thus suggesting that a "priming" is required to obtain an efficient mobilization.


Figure 3
View larger version (13K):
[in this window]
[in a new window]
  		Figure 3. Detection of circulating biotinylated uPAR84-95 in vivo. To determine the levels of circulating uPAR84-95 after i.p. injection, four mice were injected with 20 µg biotinylated peptide, then serum samples were collected at various intervals and analyzed in duplicate by dot-blot and ECL (A). Dot-blots were analyzed by densitometric scanning (B).

 
uPAR84-95 and G-CSF induce similar increases in circulating polymorphonuclear cell–enriched WBCs and HSCs/HPCs in mice. We then compared the HSC/HPC mobilizing capability of uPAR84-95 with that of G-CSF. G-CSF was administered daily for 5 days, as previously reported (27). G-CSF-administration induced a 2.7-fold increase of circulating WBCs, as compared with control mice treated with buffer. Mobilized leukocytes were strongly enriched in polymorphonuclear cells (PMN; Table 1 ), in accordance with previous reports (22, 27). uPAR84-95 was given daily for 2 days at a concentration of 3 mg/kg, the dose exerting the maximum effect in dose-response experiments (Fig. 2). Administration of the uPAR-derived peptide caused a 2-fold increase in circulating WBCs, as compared with control mice treated with the scrambled peptide. uPAR84-95-mobilized leukocytes were enriched in PMNs, as observed in G-CSF-induced mobilization (Table 1).


View this table:
[in this window]
[in a new window]
  		Table 1. uPAR84-95 administration mobilizes PMN-enriched WBCs in mice

 
We then analyzed circulating CD34+ HSCs/HPCs following uPAR84-95 or G-CSF stimulation. uPAR84-95 induced a 15-fold increase in circulating CD34+ HSCs/HPCs as compared with the scrambled peptide (27.4 ± 4.2/µL versus 1.8 ± 0.3/µL; P = 0.0004). Its potency was similar to that of G-CSF (25.5 ± 1.9/µL versus 1.3 ± 0.2/µL; P = 0.004; Fig. 4 ). In vitro colony-forming unit assays confirmed uPAR84-95 capability to induce HSC/HPC mobilization. Indeed, significant increases in circulating levels of all types of colonies assayed were observed following uPAR84-95 administration, as compared with the scrambled peptide injection (Fig. 5 ). The greatest relative increase occurred in the number of CFU-GMs (611.8 ± 266.2/mL versus 96.3 ± 31.0/mL; P = 0.04); this effect was somewhat lower than that induced by G-CSF (902 ± 189.2/mL versus 125.8 ± 32.4/mL; P = 0.026), but the difference was not statistically significant (611.8 ± 266.2/mL versus 902 ± 189.2/mL; P = 0.198).


Figure 4
View larger version (16K):
[in this window]
[in a new window]
  		Figure 4. uPAR84-95 and G-CSF induce similar increases in circulating CD34+ HSCs/HPCs. CD34+ cells from uPAR84-95- and G-CSF-treated mice described in Table 1 were enumerated by flow cytometric analysis. A, columns, mean of three experiments with G-CSF and five experiments with uPAR84-95; bars, SEM. B, flow cytometric analysis with anti-CD34+ antibodies of representative cases of G-CSF, buffer, uPAR84-95, and scrambled uPAR84-95 treated mice.

 

Figure 5
View larger version (14K):
[in this window]
[in a new window]
  		Figure 5. uPAR84-95 and G-CSF induce an increase in circulating CFU and do not exert additive effects. BALB/c mice were injected i.p. with 0.250 mg/kg G-CSF or buffer, daily for 5 days, with 3 mg/kg uPAR84-95 or its scrambled version, daily for 2 days, with both G-CSF and uPAR84-95 or buffer and scrambled uPAR84-95 as a control. Four hours after the last injection, mice were killed and peripheral blood was obtained by cardiac puncture. PBMCs were plated in methylcellulose in the presence of a recombinant mouse growth factor cocktail. CFU-GM, CFU-GEMM, and BFU-E were counted after 8-day incubation at 5% CO2. Columns, mean of three experiments done in triplicate; bars, SEM. *, P ≤ 0.05, Student's t test.

 
Finally, uPAR84-95 administration during G-CSF stimulations did not induce a further increase in circulating CFU-GM, BFU-E, and CFU-GEMM, thus indicating that uPAR84-95 does not act sinergistically or additively with G-CSF (Fig. 5).

These results indicate that the uPAR84-95 capability to induce mobilization of WBCs and HSCs/HPCs was similar to that of G-CSF; however, synergistic or additive effects were not observed.


   Discussion
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
References
 
uPAR is involved in cell migration, adhesion, and proliferation (2), functions that are mediated by integrins and members of the fMLP receptor family and that require the activation of G-proteins, Src-family tyrosine kinases, and extracellular signal–regulated kinases (28). A peptide epitope of uPAR, corresponding to amino acids 84-95 (AVTYSRSRYLEC) and located in the D1-D2 linking region, is endowed with potent chemotactic activity. Cleaved forms of suPAR, lacking D1 and containing this specific sequence, are unable to bind extracellular and cell-membrane uPAR ligands, such as uPA, vitronectin, and integrins (29–31); nevertheless, they acquire the capability to stimulate migration of fMLP receptor–expressing cells, even in the absence of GPI-linked uPAR (4, 7). Such suPAR fragments or the uPAR-derived peptide uPAR84-95 can also regulate in vitro activity of chemokine receptors, such as RANTES, MCP1, and SDF1 receptors, in a fMLP receptor–dependent manner (6, 32).

Cleaved forms of suPAR lacking D1 have been detected in biological fluids of individuals affected by various diseases (3). Several proteases, such as metalloproteases, elastase, and uPA, can cleave uPAR in the D1-D2 linker region without affecting the chemotactic sequence. Thus, in vivo detectable c-suPAR could contain the chemotactic epitope and could represent an active molecule with precise and distinct functional roles rather than an intermediary product of uPAR metabolism. In fact, SRSRY-containing c-suPAR has been detected in human urine and serum; chemotactic c-suPAR levels from patients affected by colorectal and prostatic carcinomas are significantly higher than those from healthy volunteers (8).

We have recently found increased c-suPAR levels in sera of HSC donors, following G-CSF treatment (6). In vitro, the c-suPAR-derived peptide uPAR84-95 induced migration of bone marrow HSCs and abolished SDF1-dependent human HSC migration. Both these effects induced by uPAR84-95 could contribute to HSC release from bone marrow. To elucidate the role that such peptide might exert on HSC trafficking in vivo, we first investigated whether uPAR84-95, which is not species specific, may induce the same effects in mice. Our results showed that uPAR84-95 can regulate in vitro migration of mouse CD34+ leukemia cells; thus, it could potentially influence HSC retention in bone marrow, favoring their mobilization into the circulation. Indeed, uPAR84-95 administration induced migration of mouse CD34+ HSCs/HPCs into the circulation to an extent similar to that observed by administering the widely used mobilizer agent G-CSF. uPAR84-95-mobilized leukocytes were strongly enriched in PMNs as observed with other previously reported mobilizer agents (22, 27). The PMN increase has been proposed as an important step in HSC mobilization because PMNs produce proteases able to degrade SDF1 and/or matrix and adhesion molecules (9, 22). In vitro colony-forming cell assays, which are generally used to identify mobilized hematopoietic stem and progenitor cells (16), showed uPAR84-95 capability to induce HSC/HPC mobilization into the circulation.

uPAR84-95-dependent effects can be obtained after only two stimulations, instead of five stimulations required by G-CSF, probably because the specific peptide acts directly on HSCs/HPCs and not by activating secondary pathways, like G-CSF. Our findings show, for the first time, that chemotactic suPAR fragments, detected in human biological fluids, are able to regulate cell adhesion and migration also in vivo, thus suggesting that their increase in some pathologies, as in acute leukemia, might not be merely a side effect of increased uPAR expression.

Moreover, the finding that uPAR84-95 exerts a HSC/HPC mobilizing activity similar to that of GCS-F suggests a potential use of the cleaved form of suPAR, or its derived chemotactic peptide, in the strategies to optimize HSC mobilization, for instance in G-CSF poor mobilizers. The possibility of using only the active peptide instead of the whole molecule could avoid side effects due to uPAR activities other than the chemotactic capability. Further in vivo studies are required to exclude toxic effects to verify the therapeutic potential and to evaluate possible clinical applications of this molecule.


   Acknowledgments
 
Grant support: European Union Framework Program 6 (LSHC-CT-2003-503297, CANCERDEGRADOME), Ministero dell'Università e della Ricerca Scientifica e Tecnologica, and AIL-Salerno.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

We thank S. Sequino for his technical assistance in handling mice.


   Footnotes
 
Note: C. Selleri and N. Montuori contributed equally to this work.

Received 4/10/06. Revised 8/11/06. Accepted 9/20/06.


   References
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 

  1. Dano K, Behrendt N, Brunner N, Ellis V, Ploug M, Pyke C. The urokinase receptor. Protein structure and role in plasminogen activation and cancer invasion. Fibrinolysis 1994;8:189–203.[CrossRef]
  2. Blasi F, Carmeliet P. uPAR: a versatile signalling orchestrator. Nat Rev Mol Cell Biol 2002;3:932–43.[CrossRef][Medline]
  3. Montuori N, Visconte V, Rossi G, Ragno P. Soluble and cleaved forms of the urokinase-receptor: degradation products or active molecules? Thromb Haemost 2005;93:192–8.[Medline]
  4. Resnati M, Pallavicini I, Wang JM, et al. The fibrinolytic receptor for urokinase activates the G protein-coupled chemotactic receptor FPRL1/LXA4R. Proc Natl Acad Sci U S A 2002;99:1359–64.[Abstract/Free Full Text]
  5. de Paulis A, Montuori N, Prevete N, et al. Urokinase induces basophil chemotaxis through a urokinase receptor epitope that is an endogenous ligand for formyl peptide receptor-like 1 and -like 2. J Immunol 2004;173:5739–48.[Abstract/Free Full Text]
  6. Selleri C, Montuori N, Ricci P, et al. Involvement of the urokinase-type plasminogen activator receptor in hematopoietic stem cell mobilization. Blood 2005;105:2198–205.[Abstract/Free Full Text]
  7. Fazioli F, Resnati M, Sidenius N, Higashimoto Y, Appella E, Blasi F. A urokinase-sensitive region of the human urokinase receptor is responsible for its chemotactic activity. EMBO J 1997;16:7279–86.[CrossRef][Medline]
  8. Resnati M, Pallavicini I, Daverio R, Sidenius N, Bonini P, Blasi F. Specific immunofluorimetric assay detecting the chemotactic epitope of the urokinase receptor (uPAR). J Immunol Methods 2006;308:192–202.[CrossRef][Medline]
  9. Fruehauf S, Seggewiss R. It's moving day: factors affecting peripheral blood stem cell mobilization and strategies for improvement. Br J Haematol 2003;122:360–75.[CrossRef][Medline]
  10. Molineux G, Pojda Z, Hampson IN, Lord BI, Dexter TM. Transplantation potential of peripheral blood stem cells induced by granulocyte colony-stimulating factor. Blood 1990;76:2153–8.[Abstract/Free Full Text]
  11. Lapidot T, Petit I. Current understanding of stem cell mobilization: the roles of chemokines, proteolytic enzymes, adhesion molecules, cytokines, and stromal cells. Exp Hematol 2002;30:973–81.[CrossRef][Medline]
  12. Papayannopoulou T. Current mechanistic scenarios in hematopoietic stem/progenitor cell mobilization. Blood 2004;103:1580–5.[Abstract/Free Full Text]
  13. Aiuti A, Webb IJ, Bleul C, Springer T, Gutierrez-Ramos JC. The chemokine SDF-1 is a chemoattractant for human CD34+ hematopoietic progenitor cells and provides a new mechanism to explain the mobilization of CD34+ progenitors to peripheral blood. J Exp Med 1997;185:111–20.[Abstract/Free Full Text]
  14. Wright DE, Bowman EP, Wagers AJ, Butcher EC, Weissman IL. Hematopoietic stem cells are uniquely selective in their migratory response to chemokines. J Exp Med 2002;195:1145–54.[Abstract/Free Full Text]
  15. Liles WC, Broxmeyer HE, Rodge E, et al. Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist. Blood 2003;102:2728–30.[Abstract/Free Full Text]
  16. Broxmeyer HE, Orschell CM, Clapp DW, et al. Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist. J Exp Med 2005;201:1307–18.[Abstract/Free Full Text]
  17. Ichikawa Y. J Cell Physiol 1969;74:223–34.[Medline]
  18. Fibach E, Hayashi M, Sachs L. Control of normal differentiation of myeloid leukemic cells to macrophages and granulocytes. Proc Natl Acad Sci U S A 1973;70:343–6.[Abstract/Free Full Text]
  19. Krause DS, Ito T, Fackler MJ, et al. Characterization of murine CD34, a marker for hematopoietic progenitor and stem cells. Blood 1994;84:691–701.[Abstract/Free Full Text]
  20. Morel F, Szilvassy SJ, Travis M, Chen B, Galy A. Primitive hematopoietic cells in murine bone marrow express the CD34 antigen. Blood 1996;88:3774–84.[Abstract/Free Full Text]
  21. Yang L, Bryder D, Adolfsson J, Nygren, et al. Identification of Lin(–) Sca1(+)kit(+)CD34(+)Flt3– short-term hematopoietic stem cells capable of rapidly reconstituting and rescuing myeloablated transplant recipients. Blood 2005;105:2717–23.[Abstract/Free Full Text]
  22. Pelus LM, Bian H, King AG, Fukuda S. Neutrophil-derived MMP-9 mediates synergistic mobilization of hematopoietic stem and progenitor cells by the combination of G-CSF and the chemokines GROß/CXCL2 and GROßT/CXCL2{delta}4. Blood 2004;103:110–9.[Abstract/Free Full Text]
  23. Levesque JP, Hendy J, Takamatsu Y, Simmons PJ, Bendall LJ. Disruption of the CXCR4/CXCL12 chemotactic interaction during hematopoietic stem cell mobilization induced by GCSF or cyclophosphamide. J Clin Invest 2003;111:187–96.[CrossRef][Medline]
  24. Carion A, Benboubker L, Herault O, et al. Stromal-derived factor 1 and matrix metalloproteinase 9 levels in bone marrow and peripheral blood of patients mobilized by granulocyte colony-stimulating factor and chemotherapy. Relationship with mobilizing capacity of haematopoietic progenitor cells. Br J Haematol 2003;122:918–26.[CrossRef][Medline]
  25. Shen H, Cheng T, Olszak I, et al. CXCR-4 desensitization is associated with tissue localization of hemopoietic progenitor cells. J Immunol 2001;166:5027–33.[Abstract/Free Full Text]
  26. Pelus LM, Bian H, Fukuda S, Wong D, Merzouk A, Salari H. The CXCR4 agonist peptide, CTCE-0021, rapidly mobilizes polymorphonuclear neutrophils and hematopoietic progenitor cells into peripheral blood and synergizes with granulocyte colony-stimulating factor. Exp Hematol 2005;33:295–307.[CrossRef][Medline]
  27. Velders GA, Pruijt JF, Verzaal P, et al. Enhancement of G-CSF-induced stem cell mobilization by antibodies against the ß2 integrins LFA-1 and Mac-1. Blood 2002;100:327–33.[Abstract/Free Full Text]
  28. Ossowski L, Aguirre-Ghiso JA. Urokinase receptor and integrin partnership: coordination of signaling for cell adhesion, migration and growth. Curr Opin Cell Biol 2000;12:613–20.[CrossRef][Medline]
  29. Hoyer-Hansen G, Ronne E, Solberg H, et al. Urokinase plasminogen activator cleaves its cell surface receptor releasing the ligand-binding domain. J Biol Chem 1992;267:18224–9.[Abstract/Free Full Text]
  30. Hoyer-Hansen G, Behrendt N, Ploug M, Dano K, Preissner KT. The intact urokinase receptor is required for efficient vitronectin binding: receptor cleavage prevents ligand interaction. FEBS Lett 1997;420:79–85.[CrossRef][Medline]
  31. May AE, Kanse SM, Lund LR, Gisler RH, Imhof BA, Preissner KT. Urokinase receptor (CD87) regulates leukocyte recruitment via ß2 integrins in vivo. J Exp Med 1998;188:1029–37.[Abstract/Free Full Text]
  32. Furlan F, Orlando S, Laudanna C, et al. The soluble D2D3(88–274) fragment of the urokinase receptor inhibits monocyte chemotaxis and integrin-dependent cell adhesion. J Cell Sci 2004;117:2909–16.[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
 BloodHome page
D. Ilkovitch and D. M. Lopez
Urokinase-mediated recruitment of myeloid-derived suppressor cells and their suppressive mechanisms are blocked by MUC1/sec
Blood, May 7, 2009; 113(19): 4729 - 4739.
[Abstract] [Full Text] [PDF]

Home page
 J. Leukoc. Biol.Home page
D. Focosi, R. E. Kast, S. Galimberti, and M. Petrini
Conditioning response to granulocyte colony-stimulating factor via the dipeptidyl peptidase IV-adenosine deaminase complex
J. Leukoc. Biol., August 1, 2008; 84(2): 331 - 337.
[Abstract] [Full Text] [PDF]

Home page
 Stem CellsHome page
D. E. Cramer, S. Wagner, B. Li, J. Liu, R. Hansen, R. Reca, W. Wu, E. Z. Surma, D. A. Laber, M. Z. Ratajczak, et al.
Mobilization of Hematopoietic Progenitor Cells by Yeast-Derived {beta}-Glucan Requires Activation of Matrix Metalloproteinase-9
Stem Cells, May 1, 2008; 26(5): 1231 - 1240.
[Abstract] [Full Text] [PDF]

Home page
 Cardiovasc ResHome page
V. W.M. van Hinsbergh and P. Koolwijk
Endothelial sprouting and angiogenesis: matrix metalloproteinases in the lead
Cardiovasc Res, May 1, 2008; 78(2): 203 - 212.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Selleri, C.
Right arrow Articles by Ragno, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Selleri, C.
Right arrow Articles by Ragno, P.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online